JTEC CORPORATION (3446) Stock Price

J-Tech Corporation partners with universities and research institutions to develop proprietary technologies into products. The company designs, manufactures, and sells precision optical components, automated equipment for life sciences, and analytical instruments. Its core products are X-ray mirrors with nano-level surface precision (brand name "OsakaMirror") and automated cell culture systems for drug discovery and regenerative medicine.

Customers include national research institutions, university researchers, and corporations, with revenue structures varying by business segment. The Optical Business derives approximately 81.8% of sales from public research institutions, while the Life Sciences & Equipment Development Business and Other Business generate approximately 83.7% and 97.4% of sales from corporate customers respectively, with revenue sources divided between research-focused and industrial-focused applications.

The company operates three core business segments: Optical Business, Life Sciences & Equipment Development Business, and Other Business (analytical equipment through subsidiaries). The Optical Business supplies high-precision mirrors and diffraction gratings for synchrotron radiation facilities. The Life Sciences segment manufactures large-scale automated culture systems, cost-effective general-purpose culture systems, and three-dimensional culture technologies. The Other Business focuses on thermal desorption spectroscopy (TDS) equipment and aims to expand orders through new product launches and improved production efficiency.

The company has established "Innovation2030," a long-term growth strategy looking 10 to 20 years ahead, with the goal of maximizing corporate value. In the near term, it plans to strengthen investor relations by distributing IR videos and enhancing information disclosure to retail investors, aiming to improve stock price and market valuation. On the organizational front, the company is building its management foundation through concrete initiatives: introducing a new personnel system based on role-based grades in July 2025 to strengthen human capital, and implementing a cloud-based core system in July 2026 to improve operational visibility and efficiency.

The company focuses investment on three pillars: the optical business, the life sciences and equipment development business, and the analytical instruments business including subsidiaries. The optical business, which specializes in high-precision mirrors for synchrotron radiation facilities, derives approximately 81.8% of sales from public research institutions. In contrast, the life sciences and other businesses are primarily corporate-focused (approximately 83.7% and 97.4% respectively), providing a diversified revenue base. The company manufactures products based on nano-level surface precision technology developed through collaborative research with universities and research institutions, differentiating itself through proprietary processes such as plasma-assisted polishing and electrochemical polishing (with two plasma-assisted polishing systems already ordered).

For new market development and business expansion, the company is accelerating its entry into the semiconductor and space sectors. It has a track record in synchrotron radiation applications including SPring-8 and SACLA domestically, and LCLS and EU-XFEL internationally. In semiconductors, inquiries from overseas markets including China and Taiwan are increasing, so the company is strengthening local maintenance and service capabilities and developing sales partners. A subsidiary has already achieved its first delivery to a Chinese company. The company aims to expand orders through multilingual catalog preparation and enhanced sales activities at specialized trade shows such as SEMICON. On the production side, it is expanding outsourcing partners and considering in-house manufacturing to reduce lead times for processes such as ruling and film deposition.

Technological innovation is core to the company's strategy, and it actively pursues industrialization of new processes through university partnerships. For semiconductor wafers, it is jointly developing next-generation materials (GaN, Ga2O3, diamond, etc.) with universities. In life sciences, it is accelerating the practical application of a mononuclear cell separation device and improvements to an automated culture system for drug discovery through AMED projects. To support these efforts, the company is expanding recruitment and capital investment, aiming to achieve "precision and innovation that competitors cannot replicate" through advances in research and development and manufacturing equipment capabilities.